Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.
复制标题
DOI：
10.1056/nejmoa1504542
复制
发表时间：
2015-09-10
期刊：
影响因子：
--
通讯作者：
Stadtmauer EA
中科院分区：
文献类型：
--
作者：
Garfall AL;Maus MV;Hwang WT;Lacey SF;Mahnke YD;Melenhorst JJ;Zheng Z;Vogl DT;Cohen AD;Weiss BM;Dengel K;Kerr ND;Bagg A;Levine BL;June CH;Stadtmauer EA
一名难治性多发性骨髓瘤患者在骨髓清除化疗（melphalan，每平方米体表面积140 mg）和自体干细胞移植后，接受了CTL019细胞输注，这是一种由抗cd19嵌合抗原受体转导的自体T细胞组成的细胞疗法。四年前，高剂量（每平方米200毫克）的自体移植只诱导了部分的、短暂的反应。自体移植后用CTL019细胞治疗导致完全缓解，在治疗后12个月的最新评估中，无进展证据，无可测量的血清或尿液单克隆蛋白。尽管在99.95%的患者肿瘤浆细胞中缺乏CD19表达，但仍实现了这种应答。（由诺华和其他公司资助；ClinicalTrials.gov编号：NCT02135406。）
A patient with refractory multiple myeloma received an infusion of CTL019 cells, a cellular therapy consisting of autologous T cells transduced with an anti-CD19 chimeric antigen receptor, after myeloablative chemotherapy (melphalan, 140 mg per square meter of body-surface area) and autologous stem-cell transplantation. Four years earlier, autologous transplantation with a higher melphalan dose (200 mg per square meter) had induced only a partial, transient response. Autologous transplantation followed by treatment with CTL019 cells led to a complete response with no evidence of progression and no measurable serum or urine monoclonal protein at the most recent evaluation, 12 months after treatment. This response was achieved despite the absence of CD19 expression in 99.95% of the patient’s neoplastic plasma cells. (Funded by Novartis and others; ClinicalTrials.gov number, NCT02135406.)